Table 1 Characteristics of critically ill patients with COVID-19 at baseline.
All patients (N = 1014) | NoC (N = 348) | LowC (N = 111) | HighC (N = 555) | |
|---|---|---|---|---|
Age at diagnosis, median (IQR), years | 62 (53–70) | 61 (49–72) | 63 (56–68) | 62 (54–69) |
Sex | ||||
Female, n (%) | 304 (30) | 100 (28.7) | 33 (29.7) | 171 (30.8) |
Male, n (%) | 709 (69.9) | 247 (71) | 78 (70.3) | 384 (69.2) |
NA, n (%) | 1 (0.1) | 1 (0.3) | 0 | 0 |
Body mass index, mean (min–max), kg/m2 | 29 (26–35) | 28 (26–34) | 29 (26–35) | 29 (26–35) |
Smoker | ||||
Past, n (%) | 110 (10.8) | 34 (9.8) | 13 (11.7) | 63 (11.4) |
Active, n (%) | 58 (5.7) | 18 (5.2) | 4 (3.6) | 36 (6.5) |
NA, n (%) | 846 (83.4) | 296 (85.1) | 94 (84.7) | 456 (82.2) |
Comorbidities, n (%) | ||||
Hypertension, n (%) | 466 (46) | 173 (49.7) | 50 (45) | 243 (43.8) |
Asthma, n (%) | 72 (7.1) | 22 (6.3) | 6 (5.4) | 44 (7.9) |
Diabetes Type 1, n (%) | 9 (0.8) | 3 (0.9) | 3 (2.7) | 3 (0.5) |
Diabetes Type 2, n (%) | 260 (25.6) | 83 (23.9) | 28 (25.2) | 149 (26.8) |
Coronary artery disease, n (%) | 148 (14.6) | 55 (15.8) | 14 (12.6) | 79 (14.2) |
Fibrosis Lung, n (%) | 9 (1.0) | 3 (0.9) | 0 | 6 (1.1) |
HIV, n (%) | 6 (0.6) | 4 (1.2) | 0 | 2 (0.4) |
Depression, n (%) | 46 (4.5) | 12 (3.4) | 7 (6.3) | 27 (4.9) |
Dementia, n (%) | 39 (3.8) | 19 (5.5) | 2 (1.8) | 18 (3.2) |
Malignoma, n (%) | 47 (4.6) | 16 (4.6) | 6 (5.4) | 25 (4.5) |
Kidney transplantation, n (%) | 28 (2.8) | 6 (1.7) | 2 (1.8) | 20 (3.6) |
NA, n (%) | 4 (0.4) | 1 (0.3) | 0 | 3 (0.5) |
SARS-CoV-2 1st infection, n (%) | 1008 (99.4) | 348 (100) | 109 (98.2) | 551 (99.3) |
SARS-CoV-2 (Feb 2020 – Oct 2020), n (%) | 169 (16.7) | 90 (25.9) | 14 (12.6) | 65 (11.7) |
Glucocorticoids, n (%) | 79 (46.7) | 90 (53.3) | 14 (8.3) | 65 (38.4) |
SARS-CoV-2 (Oct 2020 – Dec 2021), n (%) | 845 (83.3) | 258 (74.1) | 97 (87.4) | 490 (88.3) |
Glucocorticoids, n (%) | 587 (69.5) | 258 (30.5) | 97 (11.5) | 490 (58) |
APACHE II score, median (IQR) | 23 (15–30) | 16 (11–24) | 29 (20–35) | 25 (17–31) |
SOFA score, median (IQR) | 7 (2–11) | 2.5 (0–5.8) | 10 (6.5–14) | 8 (4–12) |
SAPS II score, median (IQR) | 38 (30–46) | 32 (25–41) | 43 (35–51) | 39 (31–48) |
Charlson comorbidity index, median (IQR) | 2 (1–4) | 2 (1–4) | 2 (1–4) | 2 (1–4) |
Creatinine, median (IQR) | 0.93 (0.67–1.5) | 0.85 (0.69–1.2) | 1.4 (0.73–2.2) | 0.99 (0.66–1.6) |
Urea, median (IQR) | 59 (37–90) | 45 (30–68) | 73 (50–100) | 64 (43–100) |
Renal replacement therapy, n (%) | 434 (42.9) | 45 (12.9) | 84 (75.7) | 305 (55) |
Invasive Ventilation, n (%) | 710 (70) | 120 (34.5) | 100 (90.1) | 490 (88.3) |
Norepinephrine, n (%) | 732 (72.2) | 130 (37.4) | 100 (90.1) | 502 (90.5) |
